Use of proteomic approaches to identify disease biomarkers

Lancet Neurology

Volumn 6, Issue 12, 2007, Pages 1036-1037

  Teunissen, Charlotte E ^a   Scheltens, Philip ^a,b  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; BIOLOGICAL MARKER; CYTOKINE; TUMOR NECROSIS FACTOR;

ALZHEIMER DISEASE; CEREBROSPINAL FLUID; COGNITIVE DEFECT; DEGENERATIVE DISEASE; DISEASE COURSE; DISEASE SEVERITY; HUMAN; LETTER; PREDICTION; PRIORITY JOURNAL; PROTEOMICS; SENSITIVITY AND SPECIFICITY; STATISTICAL SIGNIFICANCE;

BIOLOGICAL MARKERS; HUMANS; NEURODEGENERATIVE DISEASES; PROTEOMICS;

EID: 36148965162     PISSN: 14744422     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1474-4422(07)70276-4     Document Type: Letter

References (6)

1. Ray S., Britschgi M., Herbert C., et al. Classification and prediction of clinical Alzheimer's diagnosis based on plasma signaling proteins. Nat Medicine (2007). published online Oct 14. DOI:10.1038/nm1653
2. Wyss-Coray T. Inflammation in Alzheimer disease: driving force, bystander or beneficial response?. Nat Med 12 (2006) 1005-1015
3. de la Torre J. Is Alzheimer's disease a neurodegenerative or a vascular disorder? Data, dogma, and dialectics. Lancet Neurol 3 (2004) 184-190
4. Blennow K., and Hampel H. CSF markers for incipient Alzheimer's disease. Lancet Neurol 210 (2003) 605-613
5. Hansson O., Zetterberg H., Buchhave P., Londos E., Blennow K., and Minthon L. Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study. Lancet Neurol 5 (2006) 228-234
6. Mehta P. Amyloid beta protein as a marker or risk factor of Alzheimer's disease. Curr Alzheimer Res 4 (2007) 359-363